MRNA
NASDAQ · Biotechnology
Moderna Inc
$59.35
-4.62 (-7.22%)
Financial Highlights (FY 2026)
Revenue
1.98B
Net Income
-2,878,486,015
Gross Margin
70.3%
Profit Margin
-145.2%
Rev Growth
-53.4%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 70.3% | 70.3% | 45.8% | 45.8% |
| Operating Margin | -158.1% | -142.3% | -12.3% | -14.0% |
| Profit Margin | -145.2% | -137.9% | -12.8% | -13.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.98B | 4.26B | 2.23B | 2.33B |
| Gross Profit | 1.39B | 2.99B | 1.02B | 1.07B |
| Operating Income | -3,135,559,325 | -6,061,003,849 | -274,760,049 | -327,869,077 |
| Net Income | -2,878,486,015 | -5,564,083,791 | -285,156,561 | -311,574,543 |
| Gross Margin | 70.3% | 70.3% | 45.8% | 45.8% |
| Operating Margin | -158.1% | -142.3% | -12.3% | -14.0% |
| Profit Margin | -145.2% | -137.9% | -12.8% | -13.4% |
| Rev Growth | -53.4% | -53.4% | +3.0% | +13.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 867.70M | 867.70M | 2.72B | 2.91B |
| Total Equity | 11.82B | 11.82B | 5.26B | 5.64B |
| D/E Ratio | 0.07 | 0.07 | 0.52 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -2,916,220,389 | -5,950,191,944 | -355,384,473 | -379,950,378 |
| Free Cash Flow | — | — | -237,052,091 | -246,991,527 |